ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
[Product Overview]
ProGsterol is a peptide-based nutraceutical developed by Caregen to address the growing global burden of metabolic disorders, including insulin resistance, type 2 diabetes, and MASLD.
Its active ingredient, Deglusterol, is a proprietary peptide complex derived from Deobetide and Adiporin, designed to improve insulin receptor sensitivity and regulate glucose metabolism through multi-pathway metabolic modulation.
Formulated as a once-daily oral supplement, ProGsterol offers a convenient, non-invasive solution aligned with the increasing demand for preventive and lifestyle-driven metabolic health management.
It supports improvements in key metabolic parameters, including glucose regulation, insulin sensitivity, lipid metabolism, and body composition, making it suitable for diabetic individuals, pre-diabetic individuals, patients with metabolic imbalance, and health-conscious consumers.
These effects are mediated through key pathways, including AMPK activation, suppression of lipid-induced insulin resistance through reduction of DAG and ceramide accumulation, reduction of inflammatory cytokines such as TNF-α and IL-6, and increased adiponectin secretion, contributing to metabolic homeostasis and hepatic fat clearance.
Notably, Deglusterol completed the U.S. FDA New Dietary Ingredient (NDI) notification in March 2022, becoming the first synthetic peptide approved under this designation, reinforcing its safety profile and positioning it as a globally compliant and scientifically validated ingredient.
[Human Clinical Results]
Deglusterol (ProGsterol) improved glucose control, insulin sensitivity, liver health, and body composition across multiple metabolic conditions, supporting comprehensive metabolic regulation.
